Pharma BD Deal Intelligence
Janssen Biotech (J&J subsidiary) entered an exclusive worldwide collaboration and license agreement with Legend Biotech to develop, manufacture, and commercialize ciltacabtagene autoleucel (cilta-cel, later branded CARVYKTI), a BCMA-directed CAR-T cell therapy for multiple myeloma. J&J paid $350 million upfront with additional milestone payments. The collaboration features a 50:50 cost and profit-sharing structure globally, except in Greater China (70% Legend / 30% Janssen). CARVYKTI received FDA approval in February 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Legend Biotech Corporation (this deal) | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
| Johnson & Johnson / Genmab A/S | 2012 | $3.0B | 77 |
← Browse all deals · How we score deals
More: 2017 deals · Johnson & Johnson deals · Gene Therapy deals